title: Topical acetone treatment induces neurogenic oedema on the sensitized mouse ear: an in vivo study using transient receptor potential vanilloid 1 (TRPV1) receptor knockout mice.
abstract: OBJECTIVE
  The participation of sensory neurons and transient receptor potential vanilloid 1 (TRPV1) receptors in phorbol 12-myristate 13-acetate (PMA)-induced nerve-sensitizing effect was examined.
  
  
  METHODS
  PMA dissolved in acetone and acetone were applied to the ears of TRPV1 receptor knockout and wild-type mice. Different groups of animals received ibuprofen, anti-interleukin-1 beta (IL-1beta) antibody, resiniferatoxin (RTX) or capsaicin pretreatment. Ear thickness, myeloperoxidase activity and IL-1beta content of the ears were determined. Histological evaluation was performed.
  
  
  RESULTS
  PMA exerted potentiating action on contralateral acetone-induced ear oedema, which was inhibited by ibuprofen, topical capsaicin desensitization of the acetone-treated ear as well as by systemic RTX pretreatment. Neither the lack of TRPV1 receptors nor anti-IL-1beta antibody prevented sensitizing effect.
  
  
  CONCLUSIONS
  The TRPV1 receptor-independent potentiating action of PMA on contralateral acetone-induced ear oedema is mediated via capsaicin-sensitive afferents and prostanoids are involved. IL-1beta is not essential in this process.
authors.affiliation: Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Pécs, Pécs, Hungary.
authors.forename: G
authors.initials: G
authors.lastname: Pozsgai
authors.forename: K
authors.initials: K
authors.lastname: Sándor
authors.forename: A
authors.initials: A
authors.lastname: Perkecz
authors.forename: J
authors.initials: J
authors.lastname: Szolcsányi
authors.forename: Z
authors.initials: Z
authors.lastname: Helyes
authors.forename: S D
authors.initials: SD
authors.lastname: Brain
authors.forename: E
authors.initials: E
authors.lastname: Pintér
mesh_terms: D000096:Acetone / Q000008:administration & dosage / Q000494:pharmacology*; D000279:Administration, Cutaneous; D000344:Afferent Pathways; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000906:Antibodies / Q000494:pharmacology; D002211:Capsaicin / Q000494:pharmacology; D004224:Diterpenes / Q000494:pharmacology; D004357:Drug Synergism; D004423:Ear / Q000294:innervation / Q000473:pathology*; D004487:Edema / Q000139:chemically induced / Q000276:immunology* / Q000473:pathology; D007052:Ibuprofen / Q000494:pharmacology; D053583:Interleukin-1beta / Q000276:immunology / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009195:Peroxidase / Q000378:metabolism; D011984:Sensory Receptor Cells / Q000503:physiopathology; D050916:TRPV Cation Channels / Q000235:genetics / Q000502:physiology*; D013755:Tetradecanoylphorbol Acetate / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000906:Antibodies; D004224:Diterpenes; D053583:Interleukin-1beta; D050916:TRPV Cation Channels; C493921:TRPV1 protein, mouse; D000096:Acetone; C024353:resiniferatoxin; D009195:Peroxidase; D013755:Tetradecanoylphorbol Acetate; D002211:Capsaicin; D007052:Ibuprofen